2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
Montreh TavakkoliStefan Klaus BartaPublished in: American journal of hematology (2023)
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes. Our understanding of its molecular makeup continues to improve risk stratification, and artificial-intelligence and ctDNA-based analyses have the potential to enhance risk assessment and disease monitoring. R-CHOP and Pola-R-CHP are used in the frontline setting; chimeric antigen receptor therapy (CART) is now the new standard-of-care for most with primary refractory disease; both CART and autologous stem cell transplantation are utilized in the relapsed and refractory setting. In this review, we summarize the classification and management of DLBCL with an emphasis on recent advances in the field.
Keyphrases
- bone marrow
- diffuse large b cell lymphoma
- artificial intelligence
- epstein barr virus
- stem cell transplantation
- mesenchymal stem cells
- risk assessment
- machine learning
- deep learning
- high dose
- healthcare
- palliative care
- big data
- acute myeloid leukemia
- stem cells
- acute lymphoblastic leukemia
- low dose
- heavy metals
- quality improvement
- climate change
- multiple myeloma
- single molecule
- smoking cessation
- circulating tumor
- replacement therapy
- platelet rich plasma